| 15.4°C Dublin

Elan No to takeover

ELAN'S board of directors has unanimously rejected a higher takeover offer from Royalty Pharma.

Royalty, which is an investor in royalty streams from pharmaceuticals, last week raised its offer to buy Elan by 5pc to $6.7bn (€5.1bn).

It was the second increase in its attempt to take over the Irish biotech firm.


Privacy